Crystal Adam 4

What Happened
Crystal Adam, President (R&D) of Tango Therapeutics (TNGX), exercised 27,000 option shares on 2026-06-01 at $5.20 per share (cost $140,400) and sold a total of 27,000 common shares the same day in two open‑market transactions for combined gross proceeds of $617,571. The sales were: 6,140 shares at a weighted average price of $22.25 (≈ $136,627) and 20,860 shares at a weighted average price of $23.06 (≈ $480,944). These trades were executed under a Rule 10b5‑1 trading plan.

Key Details

• Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (timely within the usual two‑business‑day window).
• Option exercise: 27,000 shares acquired at $5.20 each, total cost $140,400.
• Open‑market sales: 6,140 shares at $22.25 (weighted avg; sale prices ranged $21.58–$22.57 per F2) and 20,860 shares at $23.06 (weighted avg; sale prices ranged $22.60–$23.42 per F3). Total sales proceeds ≈ $617,571.
• Net cash (gross proceeds minus exercise cost, before taxes/fees): ≈ $477,171.
• Filing notes: trades effected pursuant to a 10b5‑1 plan adopted October 27, 2025 (F1).
• Vesting/award note: the option reported is subject to a four‑year vesting schedule (25% on Feb 27, 2024, remainder monthly; F4).
• Shares owned after transaction: not specified in the information provided in this summary.

Context

• This is effectively an exercise of options followed by contemporaneous open‑market sales (a common cashless exercise pattern). The filing includes a derivative entry showing a 27,000‑share disposition at $0 (related to the option/vesting mechanics and reflected in F4).
• Sales were executed under a preplanned 10b5‑1 program, which typically indicates the trades were scheduled in advance rather than ad hoc insider sales.
• As always, sales by executives can be routine (tax or liquidity needs) and are not, by themselves, a definitive signal of company prospects.